(lp0
S'CYTRX CORPORATION  Files An 8-K Results of Operations and ... Market Exclusive - Mar 15, 2017 CytRx Corporation on March 15, 2017 issued a press release regarding its financial results for the year ended December 31, 2016.Form 8-K/A CYTRX CORP For: Mar 15 - StreetInsider.comStock on the Move: CytRx Corporation  - Post Registrar'
p1
aS'CytRx Granted Type B Pre-NDA Meeting with US FDA for Registration Pathway with ... PR Newswire  - Jan 4, 2017 LOS ANGELES, Jan. 4, 2017 /PRNewswire/ -- CytRx Corporation , a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, today announced that,&nbsp;...'
p2
aS"CytRx to Present at the 29th Annual ROTH Conference PR Newswire  - Mar 7, 2017 LOS ANGELES, March 7, 2017 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice&nbsp;...CytRx Corporation  traded with Volume of 1.28 Million shares in ... - The Newburgh PressCytRx Corporation's  stock price is Worth at $0.42 - Hot Stocks Point"
p3
aS'CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common ... PR Newswire  - Dec 13, 2016 LOS ANGELES, Dec. 13, 2016 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into securities purchase agreements with existing&nbsp;...'
p4
aS'CytRx Corporation Announces Pricing of $20 Million Public Offering of Common ... PR Newswire  - Jul 15, 2016 LOS ANGELES, July 15, 2016 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that it has priced a registered public offering of an aggregate of&nbsp;...'
p5
aS'CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer PR Newswire  - Dec 19, 2016 LOS ANGELES, Dec. 19, 2016 /PRNewswire/ -- CytRx Corporation , a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, has appointed Daniel&nbsp;...'
p6
aS'CytRx: The BASIC Chemistry Seeking Alpha - Oct 26, 2016 This article is meant to explain the general science of CytRx  and why they will continue to fail. We go over basic chemistry of &quot;pH sensitive linkers&quot; - the fundamental platform of CytRx. Further, we want to make it clear that although ...'
p7
aS'CytRx Corporation  Plunges 5.35% on February 23 Equities.com - Feb 23, 2017 CytRx Corporation  had a rough trading day for Thursday February 23 as shares tumbled 5.35%, or a loss of $-0.0241 per share, to close at $0.43.CytRx Corporation Risk Points versus Health Care - CML NewsStock Move to Focus: CytRx Corporation  - Is stories'
p8
aS'Stock Alert and Holding Pattern: CytRx Corporation Stock Volatility Hits An ... CML News - 18 hours ago Before we cover the full analysis we make a quick alert here that CytRx Corporation  has seen its stock price move at an amplified level.Zacks Rank on CytRx Corporation  based on Estimated Earnings - Highland MirrorRipe for A Big Move? Update on CytRx Corporation  - Morgan Research'
p9
aS'CytRx to Present at the 19th Annual BIO CEO &amp; Investor Conference PR Newswire  - Feb 6, 2017 LOS ANGELES, Feb. 6, 2017 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice&nbsp;...'
p10
a.